Summary.-Fifteen patients undergoing surgery for Stage IIb malignant melanoma were randomly allocated either to a group who received a vaccine of BCG mixed with irradiated autologous melanoma cells, or a control group who received no further treatment. All patients were monitored sequentially for immunological competence and tumour-directed immunity, using a wide range of techniques, and the results were compared retrospectively with their clinical course.
SEVERAL trials of immunotherapy in patients with malignant melanoma using bacterial adjuvants are currently in progress or have been reported (Carter, 1976; Gutterman, 1977; Morton et al., 1976) . In some of these trials, attempts have been made to monitor the immune status of patients with regard to tumour-directed immunity or general immunocompetence. In most reports only a limited number of different parameters have been measured.
We have recently published clinical results of a controlled trial of active immunotherapy in Stage Ilb melanoma, using a vaccine of irradiated autologous melanoma cells mixed with BCG (Mclllmurray et al., 1977) . Patients in the trial were systematically monitored throughout for levels of immunocompetence and evidence of tumour immunity, using a wide range of techniques, in order to identify changes which could be correlated with their clinical course, the primary objective being to determine ways of identifying patients who would benefit from immunotherapy. The skin response of these patients to the recall antigens PPD and Varidase has been reported (Mclllmurray et al., 1977) , and the following reports their immune responses as measured by various in vitro tests.
MATERIALS AND METHODS
Patients. Fifteen patients with malignant melanoma were treated surgically for localized recurrent tumour following an original operation. They wAere judged to be tumour-free after thorough clinical examination and after isotope scans of liver, bone and brain, and radiographs of chest and skeleton were shown to be normal. They were then allocated at random to either a treatment group (8 patients) which received a vaccine postoperatively, or a control group (7 patients) without further treatment. The vaccine consisted of a mixture of live BCG (Glaxo, 3x 107 organisms) and 5x 107 autologous irradiated tumour cells, and wtas given intradermally on the 14th postoperative day as described previously (Mclllmurray et al., 1977 Cell-mediated cytotoxicity tests.-Cell-mediated cytotoxicity was measured against a long-term melanoma cell line, NKI-4, using a previously described microcytotoxicity test (Embleton et al., 1976 Viable cells in suspension were used in a membrane fluorescence test as previously described (Baldwin et al., 1971) Aliquots of 2 x 105 leucocytes were set up in culture in microtest plates using RPMI 1640 medium with a bicarbonate/CO2 buffer system. The individual culture volumes of 0-22 ml included 10% autologous or AB serum. The following mitogens were added (or saline as control) in a further 0-02 ml: purified phytohaemagglutinin (Burroughs Wellcome; PHA) at 1.0 ,ug/ml and 0 5 jug/ml; concanavalin A (Miles: Con A) at 50 Hg/ml, and pokeweed mitogen (Gibco; PWM) at 1/100 dilution. All concentrations given are the final concentration of the mitogen in the cultures.
3H-thymidine (sp. act. 200 mCi/mmol) in 0-02 ml was added 24 h before harvesting at ,90 h of culture. This level of specific activity was selected to give the least error due to the inherently variable cold thymidine pool (Knight, S.C., personal communication). This comparatively low level of labelling gave counts of 20-30 ct/min in control wells (i.e. with saline instead of mitogen) with a normal range of responsiveness to the standard mitogens as indicated in Table I . Stimulation was expressed as the increment in ct/min over that found in the saline controls.
Serum immunoglobulins and complement.-IgA, IgG, IgM, C3 and C4 were measured by radial immunodiffusion (Mancini et al., 1965) and IgE was measured by radioimmunoassay. CH50 was determined by the method of Mayer (1973 Immunological tests Cell-mediated cytotoxicity (cf. normal donor) * (%) Cell-mediated cytotoxicity (cf. medium) (%) Leucocyte migration index Complement-dependent cytotoxicity (%) Fixed cell immunofluorescence (%) Membrane fluorescence index PHA (1 ,ug/ml) AB serum (ct/min) PHA (1 ,ug/ml) autologous serum (ct/min) PHA (0-5 ,ug/ml) AB serum (ct/min) PHA (05 ,ug/ml) autologous serum (ct/min) PWM AB serum (ct/min) PWM autologous serum (ct/min) Con A AB serum (ct/min) Con A autologous serum (ct/min) C'3 (mg/100 ml) C'4 (mg/100 ml) C'Ho5 (titre)
IgG (mg/100 ml) IgA (mg/100 ml) IgM (mg/100 ml) IgE (units/ml) IgD (mg/ml) Haemoglobin (g/100 ml) * Cell-mediated cytotoxicity was calculated with reference to cytotoxicity by normal donor mononuclear cells (cf. normal donor) and also by reference to target cell survival in culture medium alone (cf. medium).
t Cell-mediated cytotoxicity (cf. medium) and IgD measurements showed significant differences between vaccinated and control patients (P<0.05). No other differences are statistically significant. slightly higher in the group subsequently given vaccine than in controls or normal subjects (P < 0.05) and both melanoma groups showed slightly inhibited leucocyte migration following treatment with melanoma extract, compared with normal people. However, these differences were not very great, and none of the serological tests showed any significant difference between either melanoma group or normal donors. Lymphocyte stimulation by PHA was lower in the melanoma patients than in normal individuals, but still well above background levels; stimulation in AB serum was lower in patients who were subsequently vaccinated than in those who were not. In both groups of patients, the stimulation was less in autologous serum than in AB serum. With the exception of the raised ESR, the mean values for the various haematological and serological parameters were within the normal range. Apart from cell-mediated cytotoxicity, the only significant difference between vaccinated and control patients was the lower IgD level in the vaccinated group (P < 0.05).
Secondly, patients who remained tumour-free for 12 months were compared with those who developed recurrent tumour within 12 months of surgery. The mean 2-week postoperative values (+ s.e. mean) for these patients are shown in Table II . Again, the results of tests for tumourdirected immunity showed both groups to be similar and no differences emerged which could be associated with varying prognosis. Serum Ig, complement and enzyme levels, and white-cell counts were also similar in both groups. There were differences in the effect ofautologous serum on lymphocyte responses to PHA between the 2 groups. Thus, autologous serum inhibited PHA responsiveness at a PHA concentration of 1 /tg/ml but this effect was more marked in patients who later Immunological tests Cell-mediated cytotoxicity (cf. normal donor) (%) Cell-mediated cytotoxicity (cf. medium) (%) I,eucocyte migration index Complement-dependent cytotoxicity (%) Fixed cell immunofluorescence (%) Membrane fluorescence index PHA (1 ,ug/ml( AB serum (ct/min) PHA (1 ,tg/ml) autologous serum (ct/min) PHfA (0-5 ,tg/ml) AB serum (ct/min) PHA (0-5 ,ug/ml) autologous serum (ct/min) PWM AB serum (ct/min) PWM autologous serum (ct/min) Con A AB serum (ct/min) Con A autologous serum (ct/min) C'3 (mg/ 100 ml) C'4 (mg/100 ml) C'H50 (titre) IgG (mg/100 ml) IgA (mg/100 ml) IgM (mg/100 ml) IgE units/ml IgD (mg/ml) Haemoglobin (g/100 ml) (McIlimurray et al., 1977) and were thereafter exclutded from the study; complete data for-all patients were therefore obtained only up to 3 months after treatment. Some changes appeared in the cell-mediated cytotoxicity and lymphocyte-stimulation tests, and the values for these tests at 3 months are shown in Table 111 . Cellmeediate(1 cytotoxicity compared with medium controls increased from the low initial level of 6 to 26% at 3 months in control patients. Cytotoxicity in tumourfree patients was similarly raised at 3 months. In contrast, the value in vaccinated patients developing recurrent tumours fell from an initial 410% to 80% at 3 months, although tumour-recurrent control patients showed similar cytotoxicity to tumour-free patients at 3 months. Stimulation by Con Hellstr6m et al., 1973; Heppner et al., 1973; Bodurtha et al., 1976) , leucocyte migration inhibition (McCoy et al., 1975; Lieberman et al., 1975) or lymphocyte stimulation by melanoma extracts (Spitler et al., 1976; Lieberman et al., 1975) . In this report, a wide range of non-specific and tumour-directed immunie phenomena has been investigated on the same patients repeatedly, so that a retrospective comparison could be made on,the results of these and the clinical outcome. The clinical results of this study have been published (Mclllmurray et al., 1977) . It was soon apparent that a number of vaccinated patients relapsed more quickly than controls, so the trial was stopped at an early stage. Consequently the numbers in both control and vaccinated groups were small and, together with the variability experienced, this meant that most of the differences observed were not statistically significant. In spite of this, however, certain trends were observed and some conclusions can be drawn from the study.
Attempts to find correlations between prognosis and tumour-directed immunity were essentially negative. No evidence of increased serological activity could be detected in melanoma patients compared with normal donors, and none of the patient groups (control, vaccinated, tumour-free or tumour-recurrent) was significantly different from another. Also, little 0-0 difference was observed between any of
